Image

ePRO in Advanced Lung Cancer: Emotional Distress, Symptom Burden, Brain Metastasis

ePRO in Advanced Lung Cancer: Emotional Distress, Symptom Burden, Brain Metastasis

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This study intends to adopt a prospective longitudinal research design to comprehensively evaluate patient-reported emotional stress and symptom burden in patients with advanced lung cancer and lung cancer brain metastasis during first-line and maintenance treatment, extract symptom clusters, and describe the longitudinal dynamic trajectories of symptoms and symptom clusters over time. Meanwhile, it analyzes the relationships between brain metastasis and emotional stress as well as symptom trajectories.

Patients will be divided into three cohorts according to the status of brain metastasis: non-metastasis, stable brain metastasis, and progressive brain metastasis. Differences in emotional stress, symptom burden and symptom cluster manifestations among subgroups will be further compared, together with their correlations with brain metastasis. This study aims to improve the understanding of the characteristics of symptom burden and symptom cluster profiles mediated by emotional stress in lung cancer patients throughout treatment.

Eligibility

Inclusion Criteria:

  1. Non-brain metastasis cohort: patients with stage IV non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) confirmed by pathology and imaging, without brain metastasis; Brain metastasis cohort: patients with pathologically and radiologically confirmed stage IV NSCLC and SCLC accompanied by brain metastasis;
  2. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2;
  3. Age ≥ 18 years old;
  4. Estimated survival time ≥ 3 months;
  5. Capable and willing to repeatedly complete electronic questionnaires via smartphones or tablets;
  6. All enrolled patients signed the hospital-approved informed consent form.

Exclusion Criteria:

  1. Prior receipt of anti-tumor treatment;
  2. Complicated with severe chronic diseases of the heart, liver, kidney and other vital organs;
  3. Abnormal consciousness or mental status;
  4. Inability to understand the research content and requirements;
  5. A previous medical history of other malignant tumors.

Study details
    Lung Cancer
    Brain Metastasis
    Patient Reported Outcome

NCT07912190

Qian Chu

7 November 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.